$LYEL Cashflow Statement | Understand Stock

$LYEL

$10.12 +$0.81 (8.7%) Close

$LYEL Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Acquired IPR&D expense
Stock-based compensation expense
Loss on securities purchase agreement put/call
Depreciation and amortization expense
Net amortization and accretion on marketable securities
Loss on remeasurement of convertible preferred stock tranche liabilities
Expense in connection with equity issuances
Non-cash lease income
Loss on property and equipment disposals, net
Expense in connection with asset acquisition
Change in fair value of contingent consideration payable
Impairment of long-lived assets
Change in fair value of success payment liabilities
Change in fair value of equity warrant
Gain on other investments
Gain on net operating lease liability disposal
Impairment of other investments
Loss (gain) on marketable equity security
Changes in operating assets and liabilities:
Prepaid expenses, other current assets and other assets
Accounts payable
Accrued liabilities and other current liabilities
Deferred revenue
Operating lease liabilities, non-current
Other non-current liabilities

Net cash used in operating activities
CASH FLOWS FROM INVESTING ACTIVITIES
Purchases of property and equipment
Sales of property and equipment
Purchases of marketable securities
Maturities of marketable securities
Purchases of other investments
Acquisition of assets, net of cash acquired
Net cash provided by investing activities

CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from securities purchase agreement equity issuance
Proceeds from exercise of stock options
Proceeds from employee stock purchase plan
Taxes paid related to net share settlement of equity awards
Proceeds from initial public offering, net of issuance costs
Proceeds from issuance of convertible preferred stock, net of issuance costs
Payments for the repurchase of common stock
Payments for the repurchase of convertible preferred stock
Net cash provided by financing activities

Net (decrease) increase in cash, cash equivalents and restricted cash
Cash, cash equivalents and restricted cash at beginning of period
Cash, cash equivalents and restricted cash at end of period
SUPPLEMENTAL CASH FLOW INFORMATION
Cash paid for amounts included in the measurement of lease liabilities
Cash received for amounts related to tenant improvement allowances
Non-cash investing and financing activities:
Equity issued for Acquisition (Note 3)
Securities purchase agreement put/call issuance
Equity issued for contingent consideration - ImmPACT Bio USA Inc. acquisition
Contingent consideration payable related to the purchase of the IPR&D asset on Closing Date (Note 3 & 8)
Purchases of property and equipment included in accounts payable and accrued liabilities
Acquisition of PACT Series D convertible preferred shares
Conversion of convertible preferred stock to common stock upon closing of initial public offering
Operating lease right-of-use assets obtained in exchange for lease obligations
Other investments received for sale of assets
Non-cash deemed dividends on convertible preferred stock
Remeasurement of operating lease right-of-use asset for lease modification

Represented by:
Cash and cash equivalents
Restricted cash

Comments